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ABSTRACT: Telmisartan suffers from low oral bioavailability due
to its poor water solubility. The research work presents a
formulation of solid dispersed (SD) telmisartan formulation as a
ternary mixture of a drug, a polymeric carrier (poly-
(vinylpyrrolidone) (PVP) K30), and an alkalizer (Na2CO3). The
preparation method, which was lyophilization of an aqueous
solution containing the ingredients, was free from any organic
solvent. The developed SD formulations resulted in a significant
improvement in in vitro dissolution (>90% drug dissolution in 15
min) compared to pure telmisartan. Solid-state characterization by
scanning electron microscopy (SEM), differential scanning
calorimetry (DSC), and X-ray diffraction (XRD) studies indicated
the conversion of crystalline telmisartan into an amorphous form.
Fourier transform infrared (FTIR) spectroscopy revealed the drug−polymer interaction that was responsible for reducing the
chances of recrystallization. A short-term stability study showed that selected SD formulations were stable in terms of in vitro
dissolution and retained their amorphous structure in ambient and accelerated conditions over 2 months. Selected formulations
(drug/PVP K30/Na2CO3 as 1:1:2 or 1:2:2 weight ratio) resulted in >2.48 times relative oral bioavailability compared to marketed
formulations. It was considered that the incorporation of an alkalizer and a hydrophilic polymer, and amorphization of telmisartan by
lyophilization, could enhance in vitro dissolution and improve oral bioavailability.
■ INTRODUCTION
Low aqueous solubility of active pharmaceutical ingredients
(APIs) causes poor dissolution in the gastrointestinal tract,
which in turn may hinder its oral bioavailability.1 Hence, the
formulation scientists need to overcome the challenge of low
aqueous solubility, especially for oral dosage form design. More
specifically, drugs that undergo dissolution rate-limited
absorption, mainly biopharmaceutical classification system
(BCS) class-II drugs with poor solubility but high permeability,
are common candidates for solubility or dissolution rate
enhancement.2 Different approaches to developing formula-
tions or drug delivery systems for such a class of drugs have
been adopted by pharmaceutical researchers and industries.
The approaches include but not limited to micronization of
APIs,3 nanoemulsions,4 self-emulsifying delivery systems,5
inclusion complexes,6 solid dispersion (SD),7 etc. Solid
dispersion or dispersion of API in a fully or partially
amorphous form or solid solution in a suitable carrier matrix
is one of the effective and easy-to-adopt techniques to improve
the apparent solubility of the API.
Solid dispersion can be prepared by many ways such as melt
mixing, hot-melt extrusion, and solvent evaporation by a rotary
evaporator or spray dryer or freeze dryer. It is not wise to
conclude which method is the best because each has its pros
and cons. For instance, melt extrusion is an industrially scalable
method and free from solvent use but needs a low-melting-
point polymeric carrier and requires that the API should be
heat-stable at the melting temperature of the carrier.8 In the
other hand, spray drying could use low temperatures but its
inherited complexity in terms of process optimization and final
product attributes are among the major challenges.9 Lyophi-
lization or freeze-drying is another method of preparing solid
dispersion.10 Principally, it works on prefreezing and
sublimation under low pressures and hence devoid of applying
heat. Therefore, it is suitable for formulating heat-sensitive
APIs into solid dispersion. Lyophilization allows a fully
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aqueous solution to be converted into powder, which has made
it an environmentally friendly “green” approach. The method
of preparation of solid dispersion has a significant impact on
product properties such as the degree of amorphization and
stability. Hence, the selection of a desirable method is very
important for solid dispersion.9 In our research, we have
adopted the lyophilization technique to prepare a telmisartan
(TEL) solid dispersion system.
Telmisartan (TEL) (chemical name, 4′-((1,4′-dimethyl-2′-
propyl(2,6′-bi-1H-benzimidazol)-1′-yl)methyl)-(1,1′-biphen-
yl)-2-carboxylic acid) is an angiotensin receptor II blocker.11
Therapeutically, it is used as an antihypertensive medication in
cardiac patients. It is manufactured or supplied as a free acid
form. Telmisartan has poor aqueous solubility and high
permeability, and hence, it is classified under BCS II. The
oral bioavailability of telmisartan is retarded due to its
inherited poor aqueous solubility. Therefore, if the solubility
of telmisartan could be improved, the oral bioavailability would
also improve.12 Telmisartan is amphoteric in nature and readily
ionizable, indicating pH-dependent solubility.13 Within the
range of pH 3−9, telmisartan is poorly soluble with reported
solubility as low as less than 1 μg/mL. The pKa value of
telmisartan was reported as 4.45 ± 0.09.14 Several attempts
have been made by different researchers to enhance
telmisartan solubility and oral availability such as inclusion
complex formation with cyclodextrin,15 solid dispersion with
chitosan,16 a nanostructured lipid carrier,17 solid dispersed
telmisartan with sn alkalizer.12 In all of the cases, telmisartan in
“special” formulations had resulted in higher dissolution and,
in some reported cases, higher bioavailability.
Modulation or alteration of the intrinsic pH of a system is an
established concept that has been applied to control the
solubility of a poorly soluble drug. It has been evidenced that
pH modification of the dosage forms can effectively improve
the dissolution rate of readily ionizable weakly acidic or basic
drugs.18 A pH modifier can change the microenvironmental
pH of a system that could manipulate the release rate of an API
if it is readily ionizable. The use of an alkalizer as a pH modifier
in a solid dispersion system has been studied by different
researchers.18,19 Recently, there is a study that used tartaric
acid (weak acid) as a pH modifier to improve the dissolution
(%) rate of telmisartan solid dispersion prepared by the solvent
evaporation method using ethyl alcohol.20
A solid dispersion system usually contains a hydrophilic
carrier that not only helps to keep the amorphous dispersion
stable but also helps in solubility improvement of the API. In
general, the apparent solubility of the API from solid
dispersion increased with increasing concentration of the
carrier in the system. However, the use of a carrier above
certain concentration is not well practicable because of the less
desirability of the formulation in terms of excess excipients.
More specifically, this is a disadvantage of the solid dispersion
approach. Hence, if modulation of microenvironmental pH is
enhanced, resulting in improvement of the solubility of the
API, then the inclusion of an alkalizer can reduce the amount
of the polymeric carrier in the system. The reduced carrier
amount combined with the alkalizer can produce a better solid
dispersion system with improved dissolution.
In this research, we have developed a solid dispersion (SD)
formulation containing telmisartan, a polymeric carrier (poly-
(vinylpyrrolidone) (PVP) K30), and an alkalizer (sodium
carbonate, Na2CO3). The use of an alkalizer has proved
effective by another research work using telmisartan by
Marasini et al.19 They have dissolved the drug in methanol
and employed the spray drying technique. Compared to his
work, in our research, we have employed the freeze-drying
technique using the only aqueous vehicle. The use of organic
solvents has been avoided. The innovator’s telmisartan tablet
formulation, Micardis (Boehringer Ingelheim) consists of
sodium hydroxide as an alkalizer and meglumine and sorbitol
as a solubilizing agent or water-soluble inactive excipients. The
tablet also contains povidone and magnesium stearate. In the
developed formulation by the present research, we have
reduced the number of excipients using one alkalizer and one
hydrophilic polymer only. The developed formulation was
characterized for the solid-state property by diffusion thermal
calorimetry (DSC), Fourier transform infrared (FTIR) spec-
troscopy, scanning electron microscopy (SEM), and powder X-
ray diffractometry (PXRD). Two separate 2 months of stability
studies in accelerated and ambient conditions were carried out.
Finally, the developed formulation was subjected to an in vivo
study in an animal model to assess the oral bioavailability and
compare it with the marketed product.
■ RESULTS AND DISCUSSION
Solubility of Telmisartan. Telmisartan, classified as a
poorly water-soluble drug, resulted in 0.004 g/L solubility in
water. However, it showed higher solubility in an acidic
medium (pH 1.2) due to the presence of two imidazole
groups. The resulting solubility values of telmisartan in our
experiments were 0.524, 0.026, and 0.007 g/L in 0.1 N HCl,
phosphate buffer pH 7.5, and phosphate buffer pH 6.8,
respectively, which mean that the lowest solubility was in
normal distilled water and the highest was in the acidic
medium. Due to poor solubility but high permeability,
telmisartan is categorized as a drug under BCS class II and
exhibits pH-dependent solubility.21 The saturation solubility of
telmisartan is quite higher in the acidic medium. Again, in a
basic medium with increasing pH, telmisartan solubility
increases. At pH 7.5, telmisartan solubility is higher than that
at pH 6.8. The solubility of ionizable telmisartan increases with
highly acidic or highly basic pH, but at neutral pH, it decreases.
A similar fashion of pH-dependent telmisartan solubility was
observed by other researchers.21
Miscibility with PVP K30.Miscibility study results showed
that with increasing polymer concentration from 1 to 7%, the
solubility of telmisartan in the aqueous polymeric medium
increases in a good linear fashion (Figure 1). In the previous
study also, we have observed the same phenomena with PVP
K30 and other polymers.7 The ΔG0t values calculated from the
miscibility study were all negative and within the range of
Figure 1. Miscibility of telmisartan with PVP K30 (polymer) at
varying concentrations; polymer conc w/w: concentration of PVP
K30 in water.
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−0.697 to −0.105 J/mol. Gibbs energy values changed in
ascending order with increasing polymer concentration.
The increasing amount of the hydrophilic polymer can
increase drug solubility. Although the exact mechanism is not
clear, it can be assumed that a weak drug−polymer complex is
one of the reasons. The drug and polymer may interact by
forming different types of interactions such as hydrogen bonds,
electrostatic interactions like ion-ion or dipole−dipole
interactions, etc.22 PVP K30 was chosen as a polymeric carrier
because of its high compatibility with many drugs, high melting
point, high tolerance in the human body, and high popularity
as a carrier in solid dispersion to prevent crystalline drug
precipitation while maintaining supersaturated state in the
gastrointestinal medium.23 The linear relationship between the
PVP K30 concentration and drug solubility has strengthened
the selection of PVP K30 for the research. The Gibbs free
energy is calculated to assess the spontaneity of the
solubilization process. In this study, all ΔG0t values are negative
at all polymeric concentrations, indicating the spontaneous
nature of solubilization. Generally, decreasing negative values
of ΔG0t (<0) indicates better solubilization and the values are
also proportionate to the concentration of polymeric carriers.24
In accordance with the theory, in our research, the highest
concentration of PVP K30 (7%) has resulted in the lowest
Gibbs energy value and the highest drug solubility, indicating a
favourable reaction. The studies could go beyond 7%
polymeric concentration, but to restrict the amounts of
inactive ingredients or carrier, we have not studied PVP K30
concentrations beyond 7%.
Lyophilization. The major advantages of the lyophilization
method include the ability to use no organic solvent and the
formation of fine amorphous particles. In our reported method
of preparing solid dispersion, we have not used any organic
solvent. We have introduced one homogenization step by an
overhead homogenizer in preparing colloidal dispersion of the
ingredients before prefreezing. In our preliminary study (data
not shown), we have observed that lyophilized dry powder,
obtained from homogenized dispersion, resulted in higher drug
solubility compared to that of nonhomogenized one. High-
speed homogenization can reduce the size of solutes in the
medium, which could be distributed evenly at fine particle size
throughout the medium. Homogenization at a high pressure
followed by lyophilization is often applied to prepare a
nanoparticulate system such as solidified nanodispersion.25
Valsartan has been prepared a nanosuspension by homoge-
nization followed by lyophilization, which showed enhanced
drug release as a result of reduced particle size and increased
surface area.1 In our research, we have used high-speed
homogenization for better formation of colloidal dispersion
before freeze-drying, which has eventually resulted in enhanced
dissolution compared to nonhomogenization (data not
shown). All of the solid dispersion formulations reported in
this article have been prepared following the same method-
ology. The final powder was loose, white powder that could be
easily recoverable from the glass apparatus. The yield of the
final product recovered from the glass container was >92% in
all cases.
%Drug Content. The results of the analysis of the drug
content (%) considering the quantity of powders equivalent to
40 mg of telmisartan for solid dispersion formulations was
found to be within the range of (99.15 ± 1.16)−(101.2 ±
1.23), and these values are within the acceptable range (Table
1). Low values of standard deviation (SD) for the drug content
indicate uniformity in drug distribution in all of the solid
dispersion formulations.
Selection of Optimum Formulation Based on In Vitro
Dissolution Study. The dissolution medium as per the
compendia for telmisartan is phosphate buffer pH 7.5. The
same medium was used to screen the developed SDtelmi
formulations prepared as per Table 4 with varying concen-
trations of Na2CO3 and PVP K30. Two formulations (F12,
F13) were prepared without Na2CO3 to compare the effect of
alkalizer on in vitro dissolution. The result of the in vitro
dissolution study is presented in Figure 2. It was observed that
there were significant differences in the in vitro dissolution
profile between F12, F13, and other SDtelmi. While the lowest
percent dissolution from SDtelmi was 73% in 60 min (F8), F12
and F13 showed percent drug dissolution of only 26.14 and
30.33% in 60 min. The results showed that without the
alkalizer, only PVP K30 in low concentrations (2 and 3 g with
respect to 1 g of telmisartan) was not able to enhance the
telmisartan dissolution significantly. Being a hydrophilic carrier
matrix, PVP K30 has the ability to enhance dissolution of the
poorly water-soluble drug, but in the case of telmisartan, a drug
with pH-dependent solubility, the presence of an alkalizer
matters significantly. In another study, the same phenomena
have been reported, where without the alkalizer, PVP K30
alone (drug/PVP K30, 1:3 weight ratio) could not enhance
telmisartan dissolution significantly.26 This dissolution en-
Table 1. Drug Content of Telmisartan in Different Solid
Dispersion Formulations
formulations % drug content
F1 101.2 ± 1.23
F2 100.5 ± 0.92
F3 101.05 ± 0.79
F4 99.2 ± 1.31
F5 99.59 ± 1.91
F6 101.24 ± 0.66
F7 99.88 ± 1.55
F8 99.15 ± 1.16
F9 100.79 ± 0.48
F10 99.95 ± 1.33
F11 100.22 ± 0.55
F12 99.59 ± 1.19
F13 99.53 ± 1.12
Figure 2. In vitro dissolution profile of telmisartan solid dispersion
with the alkalizer (F1, F2) and without the alkalizer (F12, F13). The
value within parentheses against each formulation represents the
composition by weight ration of telmisartan/PVP K30/Na2CO3. Each
time point is representative of mean data ± SD (n = 3).
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hancement occurred due to the modulation of micro-
environmental pH by the alkalizer in the formulation. In the
presence of the hydrophilic carrier, when the SDtelmi becomes
wet by the dissolution medium, Na2CO3 starts dissolving
immediately. The pH of the surrounding microenvironment
increases to a high basic level, which makes telmisartan soluble
at a higher rate and extent.19 This enhanced dissolution is
attributed to the enhanced solubility of telmisartan in the
presence of Na2CO3.
In vitro dissolution profiles with respect to time for all
formulations studied have been described in Figure 3. Out of
all 11 SDtelmi formulations, except F8, all of the 10 SDtelmi
formulations resulted in more than 90% dissolution within 15
min. However, the marketed product resulted in 76.57% drug
release within 15 min. Pure telmisartan powder resulted in very
low (less than 5%) drug dissolution within 60 min. Out of the
11 SDtelmi formulations (F1−F11), the lowest concentration of
Na2CO3 was 2 g with respect to 1 g of drug. Statistical analysis
using one-way analysis of variance (ANOVA) (Tukey test)
showed no significant difference in the dissolution of F1−F11
except for F8 at 15 min with the p-value <0.05 (Figure S1).
Despite the insignificant improvement in dissolution from F12
and F13, in the presence of only PVP K30, it can be said that
PVP K30 has a major role in drug dissolution. The results from
F12 and F13 might be due to insufficient polymer
concentration to make an amorphous solid dispersion.
Although the drug−polymer miscibility study showed that
increasing polymer concentration shall increase drug solubility
in the aqueous medium, but from the dissolution profile
derived in this research, no such effect of polymer
concentration−solubility relationships in in vitro dissolution
could be established. By Figure 4, if we compare the
dissolution at 5 min between different formulations of fixed
Na2CO3 but varying PVP K30, we can see that increasing PVP
K30 causes lesser dissolution. For instance, in Figure 4A, the
order of drug dissolution at 5 min is F1 > F2 > F3 > F6 > F9
with the highest at 91.56% (F1) and the lowest at 81.67%
(F9). The same trend was observed in the case of F4, F7, and
F10 (Figure 4B). PVP K30, due to its hydrophilic nature,
reduces interfacial tension to dissolution medium that
contributes to drug wettability. Increased drug wettability
causes the formation of a microenvironment surrounding the
particles and enhances solubilization. PVP K30 solubilizes the
drug and maintains a supersaturated state in the gastro-
intestinal fluid without precipitation.27 But after a certain level
of concentration, PVP K30 forms a gel-like layer surrounding
the particle. Water penetrates slowly through the layer and
drug dissolution occurs via erosion.24 After a certain time,
erosion becomes complete and drug dissolution occurs rapidly.
That is why at 15 min or later time points drug dissolution
becomes almost equal in all SDs (Figure 4C). Only F8 showed
a cumulative dissolution of 71.24% within 60 min, which is the
lowest among all SDtelmi formulations with the highest
concentration of the alkalizer.
To assess the effect of freeze-drying on the dissolution of
solid dispersion, we have compared in vitro dissolution of the
physical mixture of telmisartan, Na2CO3, and PVP K30 in two
compositions like F1 and F2, termed as PMF1 and PMF2,
respectively. The cumulative percent dissolution of telmisartan
from PMF1 and PMF2 was 69.18 and 73.34%, respectively, in
60 min (Figure 3). The result was comparable with the
marketed tablet but lower than all SDtelmi. These results
indicated that other than the presence of PVP K30 and
Na2CO3, the nature of the lyophilized powder also influences
Figure 3. In vitro dissolution profile of all SDtelmi formulations,
marketed formulation (marketed TEL), pure telmisartan (pure TEL),
physical mixture (PM F1 and PM F2). The value within parentheses
against each formulation represents the composition by weight ratio
of telmisartan/PVP K30/Na2CO3. Each time point is representative
of mean data ± SD (n = 3).
Figure 4. In vitro dissolution profile of all solid dispersed telmisartan coded as (A) F1, F2, F3, F6, F9; (B) F4, F7, F10; and (C) F5, F8, F11. The
value within parentheses against each formulation represents the composition by weight ration of telmisartan/PVP K30/Na2CO3. Each time point
is representative of mean data ± SD (n = 3).
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the drug dissolution. Here comes the benefit of solid
dispersion. In solid dispersion, the drug either remains
completely miscible with the carrier to form a homogeneous
amorphous dispersion or it forms an amorphous suspension in
the carrier.28 Such molecular-level dispersion or amorphization
increases drug solubility that eventually enhances drug
dissolution.
Hence, the enhancement of dissolution from lyophilized
SDtelmi is attributed to three different factors: modulation of
microenvironmental pH by Na2CO3, beneficial effects from
PVP K30, and conversion of the crystalline drug to amorphous
or molecular dispersion. Therefore, further solid-state charac-
terization was carried out with selected SDtelmi to evaluate the
physical state of lyophilized powder. From in vitro dissolution
study, three SDtelmi were chosen which are F1, F2, and F3 due
to the three lowest concentrations of inactive ingredients with
the highest benefits as the most suitable formulations.
Functional Group Analysis. Functional group analysis
has been done by attenuated total reflection (ATR)-FTIR
study to assess the interaction between telmisartan−PVP K30
and Na2CO3. If any structural change in telmisartan occurs
within SDtelmi, then it may lead to change in functional groups.
That is why change or loss in crystallinity can be assumed from
infrared spectra. In pure telmisartan spectra (Figure 5), the
characteristic peak was obtained at 1694.11 cm−1, which is
attributed to the CO stretching of the carboxyl group. Other
significant peaks observed in pure telmisartan spectra include
3059.60 cm−1 (aromatic C−H stretching), 2956.04 cm−1
(aliphatic C−H stretching), and 1603 cm−1 (aromatic CC
bending and stretching). All of the characteristic peaks are in
close agreement with previously reported functional group
analysis for telmisartan.15 PVP K30 is characterized by strong
absorption bands at 1658.72, 2948.29, and 1283.84 cm−1 as a
result of CO stretching of the carbonyl group, C−H, and
N−C stretching, respectively (Figure 5A).29 The adsorbed
moisture in PVP K30 had caused an absorption band of 3250−
3500 cm−1 with a peak at 3411.12 cm−1. All of the peaks
including the absorbed moisture peak were also evidenced in
our previous study.7 The spectra of Na2CO3 showed the
characteristic band at 1423.15, 1065.99, and 878.08 cm−1,
indicating similarity with the reported Na2CO3 spectrum.
30 In
both of the physical mixture (1:1 weight ratio) of telmisartan
individually with PVP K30 and Na2CO3, major characteristic
peaks of the drug are visible, indicating no significant
interaction of telmisartan with other components in the dry
mix state. In PMtelmi, which is an equimolar physical mixture of
three components (Figure 5A), peaks of telmisartan at
3059.60, 2956.04, and 1603 cm−1 remain unchanged.
However, the peak at 1694.11 cm−1 was present with reduced
intensity. There might be two reasons: either peaks responsible
for the amide group of PVP K30 suppresses the telmisartan
peak in the surrounding region of 1600 cm−1 infrared wave
number or H bonding has been taken place involving the
−COOH group. However, in the telmisartan−PVP K30
mixture spectra, the peak at 1694.11 cm−1 was visible, which
is adjoined with CO stretching spectra of PVP K30 at 1658
cm−1. So, it nullifies the first reason. Therefore, it can be
assumed that some degree of interaction occurred during the
physical mixing of telmisartan with the other two components.
In the spectra of SDtelmi of F1, F2, and F3, telmisartan peaks at
1694.11, 3059.60, and 1603 cm−1 are completely absent, which
are indicative of interaction involving −COOH group (Figure
Figure 5. FTIR spectra of (A) pure telmisartan, PVP K30, Na2CO3, and individual binary mixture of telmisartan with PVP K30 and Na2CO3 and
(B) pure telmisartan and solid dispersion formulations of telmisartan (F1, F2, and F3). The value within parentheses against each formulation
represents the composition by weight ration of telmisartan/PVP K30/Na2CO3. The encircled zone of spectra indicated the characteristic
telmisartan peak at 1694.11 cm−1.
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5B). A decrease in the peak intensity due to the lowering of
vibration or the absence of carbonyl stretching from the
−COOH group along with an absence of the O−H band at
3100 cm−1 indicates the formation of strong H bonding
between two components.14 PVP K30 can form H bonding
either through nitrogen or carbonyl group of pyrrole ring
present in its structure.31 Absence of the CO peak at
1694.11 cm−1 indicates the formation of H bonding between
−COOH of telmisartan and the carbonyl functional group of
PVP K30 in SDtelmi. The dominant peak visible at around 1600
cm−1 was the peak of CO stretching of PVP K30 at 1658.72
cm−1. There was no difference of characteristic peaks of
telmisartan in terms of the position or intensity between F1,
F2, and F3, which means that the different ratio of PVP K30
did not cause any difference in interaction with telmisartan,
visible by infrared spectra.
Drugs in an amorphous state in a solid dispersion have a
tendency to precipitate rapidly into the dissolution medium
because of the supersaturated solution state. A polymeric
carrier like PVP K30 inhibits such precipitation by prolonging
supersaturation.32 The exact mechanism of how the polymer
acts as a precipitation inhibitor is still not fully clear, but it is
established that polymers like PVP K30 cause some interaction
with the drug. Drug precipitation or recrystallization occurs by
nucleation followed by crystal growth. A suitable polymeric
carrier in solid dispersion interrupts either nucleation or crystal
growth by interaction with the drug.33 Hydrogen bonding is
the most possible way of drug−polymer interaction that not
only increases the activation energy for nucleation but also
inhibits crystal growth. Hence, in this research, possible H
bonding between PVP K30 and telmisartan, evidenced by
FTIR study, can be responsible for enhanced dissolution as
well as inhibition of recrystallization of solid dispersed
telmisartan. Further structural change of telmisartan in SDtelmi
was evaluated by SEM followed by thermal analysis and finally
PXRD study.
Surface Morphology Study. The morphologies of all
three components, PMtelmi, and three different SDtelmi (F1, F2,
and F3) were evaluated by SEM analysis, and the micrographs
were obtained as the results (Figure 6). Pure telmisartan is
observed as a long needle-shaped homogeneous crystal with a
smooth texture in the SEM image, which is similar to previous
studies.26 Na2CO3 and PVP K30 were observed as irregular
fragments and round-shaped particles, respectively, in the
individual micrograph. In the ternary physical mixture of
telmisartan, Na2CO3, and PVP K30, needle-shaped telmisartan
crystals and irregular fragments of Na2CO3 are distributed on
the surface of round-shaped PVP K30. It can be said that
telmisartan still retains its crystalline structure in the ternary
mixture. The micrograph of SDtelmi (F1, F2, and F3) showed
the absence of any definite structural shape of the telmisartan
crystal. There was no difference observed apparently between
SEM images of three formulations. The absence of the
telmisartan crystal image indicates the structural change of the
drug crystal that might be attributed to the conversion of the
crystalline drug to the amorphous state by lyophilization.
However, the SEM micrograph is not very conclusive in this
case. Therefore, the change in crystallinity is further assessed
by thermal analysis and PXRD study.
Thermal Analysis. Thermal analysis gives an idea of the
physical nature of solid dispersed powder and melting and
crystallization behavior. In this research, the DSC study was
done to analyze the samples with the application of controlled
heat. The results are recorded as DSC thermograms (Figure
7). Pure TEL presented a sharp endothermic peak at about
271.74 °C, which corresponded to its intrinsic melting point,
indicating that all TEL crystals melted at that temperature and
there was no moisture adsorbed due to its highly hydrophobic
nature.34 PVP K30 had shown a broad endothermic band from
90 to 150 °C with a curve at 142 °C, which corresponds to the
melting range of PVP K30. During thermal scanning of PVP
K30, evaporation of residual moisture was observed by a broad
band due to the extremely hygroscopic nature of the PVP
polymer.7 Physical mixture (PM) had shown one small
endothermic band at around 140 °C and a small endothermic
peak at 269.99 °C, corresponding to PVP K30 and telmisartan,
respectively. The endothermic peak in the physical mixture for
TEL shifted a little bit from 271.74 to 269.99 °C. This little
peak shifting occurs due to melting point depression, which
may occur for an individual component if mixed with another
component. The endothermic peak of TEL in the physical
mixture was sharp but with reduced intensity. Such reduction
of intensity might happen from partial amorphization of
telmisartan in the physical mixture during sample preparation,
which was also evidenced by PXRD but contradicted with the
SEM image. Another reason might be partial solubilization of
telmisartan in melted PVP K30 during DSC analysis.24 There
Figure 6. SEM micrographs of pure telmisartan, PMtelmi (physical
mixture 1:1:1 weight ratio of telmisartan, Na2CO3, and PVP K30),
and solid dispersion formulations (F1, F2, F3). The value within
parentheses against each formulation represents the composition by
weight ratio of telmisartan/PVP K30/Na2CO3.
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was no new peak generated in the physical mixture, indicating
no physical incompatibility between the components of a
ternary mixture containing the drug, PVP K30, and Na2CO3.
There was no intrinsic characteristic peak for Na2CO3 over the
entire range of temperature tested from 25 to 300 °C in the
physical mixture due to its high melting point of 851 °C, as
reported in other studies.19 In the thermogram of SDtelmi (F1,
F2, and F3), no sharp endothermic peak of telmisartan was
visible. It is inferred that there was no presence of telmisartan
crystals in the sample. We have assumed the formation of an
amorphous particle in the lyophilized solid dispersion.
However, the DSC study alone is not capable of determining
the physical state of the developed product alone. Therefore,
the lyophilized dispersions were further evaluated by PXRD
analysis.
Crystallinity Analysis. PXRD tests were done to evaluate
the structural change of telmisartan in the physical mixture and
lyophilized formulations (F1, F2, and F3). Telmisartan, as
observed in the SEM image, remains as a distinct
homogeneous shaped crystal. In XRD diffractograms (Figure
8), distinctive peaks with noticeable intensities were visible for
telmisartan at 2θ angles of 6.8, 14.2, 19.1, and 22.3° with
intensities (cps) of 1095(33), 702(26), 166(13), and 252(16),
respectively. Such peaks have been observed for telmisartan by
other researchers also,26 which indicated its sharp crystal
nature. PVP K30, being an amorphous polymer did not show
any distinct peak (Figure 8). In the diffractogram of Na2CO3
(Figure 8), many peaks are visible but all above the 2θ angle of
23.76°, which means that these peaks would not interfere with
telmisartan peaks. In an equimolar ternary physical mixture
containing telmisartan, PVP K30, and Na2CO3, characteristic
peaks of telmisartan were observed but with lower intensities.
For instance, the peak at a 2θ angle of 6.8° had come up with
an intensity (cps) of 92 (10), which is considerably lower than
that of pure telmisartan. Again, the peak at 19.1° was absent in
the physical mixture diffractogram. The absence of a distinct
characteristic peak or reduction in the peak intensity in the
diffractogram indicates complete or partial loss of crystal-
linity.18 During the preparation of the physical mixture sample
for PXRD, a mild degree of cogrinding was performed using a
mortar and pestle. Possibly during cogrinding, some loss of
crystallinity occurred to telmisartan in the physical mixture.
Cogrinding of the drug and inactive ingredients such as the
polymer can cause partial amorphization of the crystalline
drug. Zhong et al. has reported reduced peak intensity at a 2θ
angle of 6.8° for telmisartan indicating conversion of the
crystalline structure to amorphous by cogrinding with
chitosan.16 However, such reduction in crystallinity in the
physical mixture in our sample is not well correlated with SEM
images, where the physical mixture showed a clear presence of
telmisartan crystals. It can be said that SEM images are not
capable of detecting partial loss of crystallinity, which is
observed in the diffractogram.
All SDtelmi formulations (F1, F2, and F3) showed the same
pattern in PXRD analysis. Characteristic telmisartan peaks at
the above-mentioned 2θ angles were absent in all three
lyophilized formulations. Peaks of Na2CO3 were present in the
PXRD diffractogram. The absence of distinct characteristic
peaks indicates the presence of a large amount of drug in the
solution in solid state, and a reduction of a large number of
characteristic peaks indicates amorphization of drug crystals.14
Therefore, it can be said that by lyophilization, telmisartan has
been converted to an amorphous form in the presence of PVP
K30 and Na2CO3 as a solid dispersion. This result is in close
agreement with SEM images and FTIR analysis. In the SEM
image, SDtelmi did not show any trace of telmisartan crystalline
structure. In the FTIR spectrum, alteration in the functional
group indicated possible structural change. Moreover, in in
vitro dissolution studies, higher dissolution rates have been
achieved from SDtelmi, behind which amorphization of
telmisartan by lyophilization is one of the significant
contributing factors. The poor water-soluble crystalline drug,
when present in the amorphous form, usually has better
aqueous solubility, which results in higher dissolution. This is
because no energy is required to break the lattice structure,
unlike the crystal form. It is speculated that in solid dispersion
after dissolution if drugs precipitate, they remain in a
metastable state, which has higher solubility.28 It is possible
Figure 7. DSC thermograms of pure telmisartan, PVP K30, ternary physical mixture of telmisartan/PVP K30/Na2CO3 (PM), and solid dispersion
of telmisartan (F1, F2, F3).
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to convert the poorly soluble crystalline drug to amorphous
solid dispersion using a suitable polymer and method of
preparation. In this research, amorphization of telmisartan was
observed for F1, F2, and F3, despite the different amounts of
the carrier, i.e., PVP K30 by the lyophilization method.
Lyophilization is a well-established technique for amorphiza-
tion of crystalline drugs, and therefore, it has been adopted to
prepare solid dispersions.35 In this research, we have managed
to cater to the advantages of lyophilization through the
enhanced dissolution of telmisartan amorphous solid dis-
persion.
Stability Evaluation. A short-term stability study for 2
months was carried out under ambient and accelerated
conditions with three SDtelmi formulations (F1, F2, and F3).
In vitro dissolution profiles of three SDtelmi formulations (F1,
F2, and F3) at 0 days and 1 and 2 months of time point are
presented in Figure 9. Functional group analysis by FTIR and
crystallinity study by PXRD has been done at 2 months of time
point.
An amorphous system is thermodynamically unstable and
tends to convert into a more stable crystalline form, which is
termed as recrystallization.28 The amorphous nature of the
drug is one of the main contributing factors behind the
improved dissolution of telmisartan from SDtelmi. Such
improvement can be compromised by recrystallization of the
drug in the solid dispersed system, which are induced by
humidity and temperature.36 Such lyophilized solid dispersed
powder particles had a wide surface area that is susceptible to
adsorb moisture. Therefore, considering its importance, an
assessment of the stability of SDtelmi was carried out in both
ambient temperature/humidity as well as under elevated
temperature/humidity (accelerated conditions). It is observed
from the dissolution profile (Figure 9) that the plots of time vs
cumulative percent drug dissolved at three different time
points, in both types of studies, are almost super-imposable on
one another for every single formulation. These results indicate
that no change in the in vitro dissolution of telmisartan
happened during two months of storage. It was assumed that
there was no or negligible occurrence of recrystallization in the
solid dispersed system. To confirm this assumption, PXRD
study was done at 2 months of time point. It was observed
from the PXRD diffractogram (Figure 10) that none of the
characteristic peaks, mentioned in Section 3.8, had come out in
any of the SDtelmi at 2 months of time point, indicating no
recrystallization of the drug. Such a result is following the
almost constant dissolution profile until the last sampling
point.
The stability of solid dispersed amorphous powder depends
on the type and concentration of the polymeric carrier.36 Two
related factors are responsible for the stability of amorphous
powder: molecular mobility and glass transition temperature
(Tg). Molecular mobility is essential for molecular diffusion
and surface integration. Diffusion causes amorphous phase
separation inside the system. A drug rich with the amorphous
phase is formed, which can relax toward molecular
conformation and induces nucleation. Thereby, crystal growth
starts and recrystallization occurs.37 Polymers, such as PVP,
plays an important role in decreasing molecular mobility by
increasing the Tg of the solid dispersed system. At low Tg
values, an amorphous system can have sufficient molecular
mobility to induce nucleation and crystal growth. Incorporat-
ing polymer with high Tg insufficient amount can thereby make
amorphous dispersion stable.36 In our study, PVP K30, used as
the polymeric carrier, has played the role of a stabilizer for
amorphous solid dispersions of telmisartan. Another factor of
reducing crystal growth is strong drug−polymer interactions to
form H bonding. To assess the H bonding between telmisartan
and PVP K30, FTIR analysis was done at the last time point.
From the infrared spectra (Figure S2), it was observed that the
formation of H bonding was consistently evidenced by the
absence of the characteristic telmisartan peak at 1695 cm−1
throughout the course of stability study for all three
formulations at both conditions. Such strong H bonding
between the drug and polymer is another responsible factor
behind the stability of lyophilized solid dispersed telmisartan
developed in this research. Adsorbed moisture on the solid
dispersed system may act as a plasticizer for the polymer and
can also break H bonding, weakening drug−polymer
interaction.38 This may promote recrystallization. In our
research, despite the presence of two moisture-sensitive
components, hydrophilic polymer and Na2CO3, moisture
adsorption was not so much to cause crystallization, as
Figure 8. Powder X-ray diffractograms of (A) telmisartan, (B) PVP
K30, (C) Na2CO3, (D) ternary physical mixture of equal weight ratio
of telmisartan/PVP K30/Na2CO3, and (E−G) solid dispersion
formulations of telmisartan (F1, F2, and F3).
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c04588
ACS Omega 2020, 5, 32466−32480
32473
evidenced in FTIR and PXRD studies. Suitable packaging is
thus required to make amorphous dispersion stable for a long
time.
Pharmacokinetic Study. The in vitro dissolution studies
were followed by solid-state characterization and short-term (2
months) stability study of the developed SDtelmi. The results of
all of these in vitro characterizations indicate the formation of
lyophilized amorphous solid dispersion of telmisartan with
enhanced in vitro dissolution. These results influenced us to
proceed with in vivo pharmacokinetic studies to evaluate
whether the in vitro beneficial effects of SDtelmi persist in in vivo
conditions. From the three selected SDtelmi formulations (F1,
F2, and F3), we have chosen F1 and F2 for pharmacokinetic
study in the rat animal model because of lesser inactive
ingredients compared to F3 with the same solid-state
characters and benefits. A validated high-performance liquid
chromatography (HPLC)−UV method within a linear range of
0.07−10 μg/mL and with 92.34−99.87% accuracy was
employed to quantify telmisartan in rat plasma. The plasma
concentration vs time profile for F1, F2, raw telmisartan
powder, and marketed formulation is presented in Figure 11.
Mean pharmacokinetic parameters, derived by noncompart-
mental analysis, with standard deviation, are presented in
Table 2.
In terms of Cmax, the order of different formulations is F2 >
F1 > marketed telmisartan > raw telmisartan. Cmax determines
the extent of drug absorption to the system. It was quite
expected that raw telmisartan would generate the lowest Cmax
because of its poor solubility. Although Cmax of F1 is higher
than marketed telmisartan formulation, both values were the
same statistically. The Cmax value of F2 is more than 2 times
compared to that of F1, indicating a statistically significant
Figure 9. In vitro dissolution study of THE short-term stability sample for solid dispersionS of telmisartan (F1, F2, and F3) in ambient and
accelerated conditions. Each time point is representative of mean data ± SD (n = 3).
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difference. This result is not in good correlation with in vitro
dissolution results, where both of the formulations have shown
>90% drug dissolution within 5 min. We assumed that the
lower concentration of PVP K30 in F1 might be the reason. An
amorphous dispersion, after administration, “springs out” the
drug in the gastric medium causing a supersaturated zone
around.32 In the gastrointestinal tract, PVP K30 prevents the
drug to precipitate out as crystals from the supersaturated
solution, which is termed as the “parachute” effect. The low
amount of PVP K30 in F1, compared to that in F2, was not
sufficient enough to inhibit the precipitation of telmisartan in
the gastrointestinal tract, although in the in vitro medium, it did
not cause any difference. The concentration of Na2CO3 was
the same in F1 and F2. Therefore, it may be affirmed that the
amount of PVP K30 in the F2 formulation made a difference in
the plasma concentration of telmisartan compared to that in
F1. However, such variation from in vitro to in vivo studies is a
common occurrence. An in-depth study and replication of the
study with a large number of animals could effectively evaluate
the case. The values of tmax in ascending order is F2 < raw
telmisartan < marketed formulation < F1 (Table 2). Statisti-
cally, there was no difference in tmax between raw telmisartan,
marketed formulation, and F1. The tmax of F2 was the lowest
(0.5 h) among all four formulations, but it was statistically the
same with the marketed formulation. tmax determines the time
taken to reach the Cmax, and it stands for the rate of absorption.
For BCS II class of drugs, if absorption is dissolution-rate-
limited, then it enters the circulation immediately once a drug
becomes soluble. Telmisartan, a BCS class II drug candidate,
has excellent permeability.39 That is why, even from raw
telmisartan, tmax was quite faster regardless of the maximum
concentration reached. However, the fastest absorption with
the lowest tmax was derived from lyophilized SDtelmi (F2).
AUC0−t and AUC0−∞ were calculated to assess the total drug
exposure to the system from various formulations and their
relative bioavailability. As shown in Table 2, AUC0‑t values of
F1 and F2 were 2.54 times and 3.45 times higher than the
marketed formulation, respectively. The AUC0−∞ value was
the highest for F2, followed by those for F1, marketed
formulation, and raw telmisartan.
Relative bioavailability, calculated using AUC0−∞ values, is
represented in Table 3. It showed that F2 and F1 resulted in
2.8 and 2.5 times higher relative bioavailability for the
marketed formulation. Compared to raw telmisartan, their
bioavailability was much higher (Table 3).
The improved relative bioavailability is a result of enhanced
solubility and dissolution of telmisartan from lyophilized solid
dispersion in the presence of the polymer and alkalizer.
Improvement of aqueous solubility and dissolution, in turn,
results in higher bioavailability because of the rapid and higher
extent of absorption.40 Not only higher bioavailability but also
point to point comparison from the plasma concentration vs
time profile (Figure 11) also showed higher telmisartan
absorption from F1 and F2 compared to the raw drug or
marketed formulation.
■ CONCLUSIONS
A solid dispersed formulation of telmisartan was prepared
using PVP K30 as a polymeric carrier and Na2CO3 as an
alkalizer by a lyophilization method. The preparation method
came up with its advantage of not using any organic solvent or
no application of heat. Telmisartan was converted to an
amorphous form from its original crystalline structure, which
helps in the improvement of solubility in the in vitro medium
as well as in vivo. The pharmacokinetic study revealed that the
lyophilized telmisartan formulation composed of a ternary
system of the drug/polymer/alkalizer (1:2:2 weight ratio) had
the highest relative bioavailability in rat with respect to the
marketed formulation. It can be concluded that improved
Figure 10. Powder X-ray diffractograms of the stability study sample
of three solid dispersions of telmisartan (F1, F2, and F3) at 2 months
time point kept under accelerated conditions. The value within
parentheses against each formulation represents the composition by
weight ratio of telmisartan/PVP K30/Na2CO3.
Figure 11. Plasma concentration vs time profile for raw telmisartan
(raw TEL), marketed formulation (marketed TEL), and solid
dispersion of telmisartan (F1, F2). Each data is represented as
mean data ± SD (n = 3). The value within parentheses against each
formulation represents the composition by weight ratio of
telmisartan/PVP K30/Na2CO3. The sample was collected at 12 h
after 8 h. However, no telmisartan was detected at 12 h.
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dissolution and enhanced bioavailability from SDtelmi occurred
due to the presence of the alkalizer, the presence of a
hydrophilic polymeric carrier, and the amorphous form of
telmisartan. The role of each factor could be critically
evaluated by an extensive in vivo study with a larger number
of animals and different compositions of the formulation.
Nevertheless, our results suggest that a lyophilized telmisartan
solid dispersion with an alkalizer could effectively improve the
drug’s oral bioavailability. This study can be further extended
to human volunteers after necessary toxicity evaluation and
other ethical considerations.
■ MATERIALS AND METHODS
Materials. Telmisartan (TEL) (assay on the anhydrous
basis, 99.8%) was purchased from Hangzhou Hyper Chemicals
Limited, China, in the form of a white crystalline powder. PVP
K30 was generously donated by IKOP Sdn Bhd, Malaysia.
Na2CO3, potassium dihydrogen phosphate (KH2PO4), potas-
sium hydroxide (KOH), and hydrochloric acid (37%) were
procured from Merck KGaA, Germany. Acetonitrile for
chromatography (HPLC grade), ethanol for plasma extraction
(absolute for analysis), and methanol for dissolving telmisartan
to prepare the standard solution (absolute for analysis) were
also purchased from Merck KGaA, Germany. Purified water for
HPLC was obtained from a Millipore system (18.2 MΩ/cm
resistivity, Milli-Q) (Millipore Corporation). Marketed
telmisartan formulation, Teleact 40 mg tablet (Sun Pharma,
Malaysia), was purchased from a local pharmacy.
Solubility Study. The solubility of raw telmisartan was
determined in distilled water, 0.1 N HCl (pH 1.2), phosphate
buffer solution pH 6.8, and phosphate buffer solution pH 7.5.
An excess amount of telmisartan was added to 5 mL of each of
the medium in a capped glass bottle and shaken by an
incubator shaker (Innova 4000) for 36 h at 100 rpm and 37 ±
2 °C. The aliquots were then centrifuged at 3000 rpm for 10
min. The supernatant layer was collected and filtered through
0.45 μm poly(tetrafluoroethylene) (PTFE) syringe filter
(Thermo scientific, Germany) followed by measurement of
absorbance by a UV spectrophotometer (Shimadzu 1800,
Tokyo, Japan) at a wavelength of 231 nm after the required
dilution. The concentration of the samples was determined
using a suitably constructed linearity plot. Each study was done
in triplicate.
Miscibility Study. Miscibility study of telmisartan with
PVP K30 was done following the method reported by Kyaw et
al. (2017). In short, an excess amount of telmisartan was added
in 10 mL of different concentrations of PVP K30 solutions
ranging from 1 to 7% (w/w) in a capped glass bottle. Then, the
bottles were shaken by an incubator shaker following the same
conditions as the solubility study. Aliquots were taken and the
same process of sample preparation and measurements were
followed as per the solubility study. The Gibbs free energy
equation was applied to indicate the process transfer of
telmisartan to the polymeric solution.22 Values of Gibbs free
energy were calculated as per the following equation
G RT S S2.303 log( / )0
t
0 sΔ = − (1)
where R, T, and S0/Ss are the universal gas constant, the
temperature in kelvin, and the ratio of molar solubility of
telmisartan in an aqueous polymeric solution to that of pure
water without the polymer, respectively.
Preparation of Solid Dispersion. Solid dispersion of
telmisartan, henceforth termed as SDtelmi (F1−F11), was
prepared by a lab-scale lyophilization or freeze-drying method
incorporating PVP K30 and Na2CO3 in an aqueous medium.
First, the aqueous solution of Na2CO3 was prepared according
to the desired concentration. Then, the required amount of
PVP K30 was dissolved in the Na2CO3 solution by constant
stirring. After that, 1 g of telmisartan was added to the solution
with constant stirring for 25 min, which is followed by
homogenization for 5 min (4000 rpm) using an overhead
homogenizer (WT130 Success Technic Industries, Malaysia).
The colloidal dispersion was then kept for prefreezing at −80
°C for 24 h. After that, it was lyophilized or freeze-dried in a
lab-scale freeze dryer (Alpha 1-2 LD plus Christ, Germany).
The white powder, derived from a freeze dryer, was then hand-
pulverized by a mortar and pestle, passed through a 350−500
μm sieve, and stored in a sealed air-tight plastic pouch in a
vacuum desiccator until further evaluations. The composition
of the formulation prepared is described in Table 4.
Determination of Drug Content. Appropriate weight of
telmisartan solid dispersion equivalent to 40 mg of telmisartan
was dissolved in 50 mL of methanol and diluted appropriately
to obtain a final concentration of 40 μg/mL. The samples were
analyzed by the HPLC method. The drug content of the solid
dispersions was determined in triplicate.
Table 2. Pharmacokinetic Parameters of Telmisartan Derived after Oral Administration of Different Formulations of
Telmisartana
parameters raw telmisartan marketed formulation F1 (1-1-2) F2 (1-2-2)
Cmax (μg/mL) 0.164 ± 0.016 0.409 ± 0.175 0.611 ± 0.303 1.363 ± 0.229
tmax (h) 1 ± 0.000 1.167 ± 0.764 1.667 ± 0.577 0.5 ± 0.00
AUC0−t (μg h/mL) 0.306 ± 0.080 1.206 ± 0.256 3.071 ± 1.189 4.161 ± 0.727
AUC0−∞ (μg h/mL) 0.333 ± 0.078 1.981 ± 0.493 4.876 ± 0.556 5.564 ± 0.630
Kel (h
−1) 0.448 ± 0.074 0.252 ± 0.194 0.198 ± 0.110 0.241 ± 0.031
T1/2 (h) 1.575 ± 0.256 4.124 ± 2.917 4.802 ± 3.619 2.910 ± 0.390
aEach data is represented as mean data ± SD (n = 3). F1 and F2: solid dispersion formulations of telmisartan. The value within parentheses against
each formulation represents the composition by weight ratio of telmisartan/PVP K30/Na2CO3.
Table 3. Relative Bioavailability of Solid Dispersion
Formulation of Telmisartan (F1 and F2) for Raw













SD F1 (1-1-2) 1464.31 246.15
SD F2 (1-2-2) 1670.86 280.88
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In Vitro Dissolution Study. In vitro dissolution studies
were carried out by a USP type II (paddle type) dissolution
tester (Copley DIS 8000, U.K.). Phosphate buffer of pH 7.5 in
a volume of 900 mL/basket was chosen as a dissolution study
medium following the USP procedure.41 Other relevant
parameters were as follows: speed of the stirrer, 75 rpm;
temperature of the medium, 37 ± 0.5 °C; aliquot volume, 5
mL. At a predetermined time intervals of 5, 15, 30, and 60 min,
sample aliquots (5 mL) from the dissolution basket were
withdrawn and an equivalent amount (5 mL) of the fresh
dissolution medium was immediately added to maintain a
constant dissolution volume. The aliquots were filtered
through a 0.45 μm syringe filter and analyzed by a
predeveloped high-performance liquid chromatography
(HPLC) method. Raw telmisartan powder (40 mg), marketed
formulation 40 mg, ternary physical mixture of telmisartan−
PVP K30−Na2CO3 (equivalent to 40 mg, composition as per
F1 and F2), termed as PM1 and PM2, and all SDtelmi
(equivalent to 40 mg) were used for in vitro dissolution studies.
In the HPLC method, used for dissolution sample analysis,
the separation was achieved on a ZORBAX Eclipse Plus C18
column (250 mm length and 4.6 mm internal diameter with 5
μm pore size). The isocratic elution method consists of 70:30
(v/v%) mixture of acetonitrile and 10 mM phosphate buffer
solution (pH 3.8) as mobile phase, 1 mL/min flow rate, 10 μL
injection volume, and UV detection system at 231 nm.
Telmisartan was detected at approximately 4.8 min within a
total chromatographic run time of 7 min.
Functional Group Analysis. Attenuated total reflectance
Fourier transform infrared spectroscopy (ATR-FTIR) study
was done to analyze functional groups present in telmisartan
and SDtelmi to evaluate interactions between the drug and
carriers. In this study, each of the components including
telmisartan, physical mixture of all three components of the
formulation in 1:1:1 weight ratio (henceforth termed as
PMtelmi), and SDtelmi formulations were subjected to scanning
over an IR range of 4000−400 cm−1 with accumulations of 15
scans at a resolution of 2 cm−1 by an IR spectrometer
(PerkinElmer, Waltham, MA). IR spectra were compared
visually and analyzed to derive the outcome.
Surface Morphology Study. Scanning electron micros-
copy (SEM) was carried out to assess the surface and shapes
morphology of SDtelmi particles. Pure telmisartan, pure PVP
K30, pure Na2CO3, PMtelmi, and SDtelmi were analyzed by SEM,
and the generated micrographs were compared visually. In
short, the method was as follows: using a pair of thumb
forceps, double-sided carbon adhesive tape was placed on the
flat surface of the SEM sample stub followed by a sprinkling of
a very small amount of sample powder on it. Then, the sample
particles were gold-coated and scanned for images using a
scanning electron microscope (ZEISS EVO 50, Germany).
Thermal Analysis. Thermal analysis was done by differ-
ential scanning calorimetry (DSC) study. For this study, the
sample (5−8 mg) was enclosed in an aluminum crucible and
exposed to a thermal range of 10−300 °C (for PVP K30, up to
200 °C) (10 °C/min increment) in a differential scanning
calorimeter (1-STARe, Mettler Toledo, Columbus, OH) under
a constant nitrogen flow (10−20 mL/min). Pure telmisartan,
PVP K30, PMtelmi, and SDtelmi were used as samples. Na2CO3
alone was not studied by DSC due to its high melting point
(around 850 °C),42 which is beyond the capacity of the
instrument used.
Crystallinity Analysis. Assessment of crystallinity was
done by powder X-ray diffraction (PXRD) analysis. The
method followed was the method narrated by Tran et al. with
minor modifications.14 Each of the individual components of
the formulations including telmisartan, PMtelmi, and SDtelmi was
scanned using an X-ray diffractometer (Rigaku Ultima IV, TX)
in increments of 0.02° from 3 to 80° at a rate of 1 s/step,
where Cu Kα radiation used was 30 kV and 15 mA. Diffraction
angles (2θ) were recorded along with intensity (counts), and
an individual diffractogram for each sample was derived.
Short-Term Stability Study. Two short-term stability
studies (2 months of duration) were done with the final SDtelmi
formulations in ambient (30 °C/75% relative humidity) and
accelerated (40 °C/75% relative humidity) conditions using a
stability chamber (M 1400, Capromax Sdn. Bhd., Malaysia) to
evaluate significant changes during storage of the SDs if any.
Samples were analyzed at 1 and 2 months by in vitro
dissolution and compared to that of the 0 day result. PXRD
and FTIR studies were also done at 2 months of time point.
Pharmacokinetic Study. A pharmacokinetic study was
done in an animal model (rat) to evaluate the in vivo
performances of developed SDtelmi formulations as well to
determine their relative bioavailability compared to the raw
drug and marketed formulation. The animal study protocol
was prior approved by the Institutional Animal Care and Use
Committee (IACUC-IIUM), International Islamic University
Malaysia (reference no.: IIUM/504/14/2/IACUC-Approval/
2017(17)). This animal study had been carried out following
the National Institutes of Health guide for the care and use of
laboratory animals (NIH Publications no. 8023, revised 1978).
Animal Husbandry and Maintenance. Male Sprague−
Dawley rats weighing 280 ± 20 g and aged 9−10 weeks were
purchased from Sapphire Enterprise, Selangor, Malaysia. The
rats were housed as three rats per cage and acclimatized with
the laboratory environment for one week on a standard 12 h
light/dark cycle at a room temperature of 25 ± 3 °C and
relative humidity of 50 ± 10%. The rats were provided with
sufficient food and water during the acclimatization period.
However, they were kept in the fasting condition with free
access to water overnight (12 h) before the start of the
experiment.
Study Design and Sample Collection. A total of 12 rats
were divided into four groups (n = 3). Each of the groups
received either pure telmisartan powder, marketed formulation
or F1 and F2 (two different SDtelmi preparations selected after
in vitro studies) by oral administration at a dose of 4 mg/kg
body weight. For SDtelmi formulations, the equivalent amount
Table 4. Compositions of the Solid Dispersion
formulations TEL (g) PVP K30 (g) Na2CO3 (g)
F1 1 1 2
F2 1 2 2
F3 1 3 2
F4 1 3 3
F5 1 3 4
F6 1 5 2
F7 1 5 3
F8 1 5 4
F9 1 7 2
F10 1 7 3
F11 1 7 4
F12 1 1
F13 1 2
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c04588
ACS Omega 2020, 5, 32466−32480
32477
to the required dose was calculated and used for oral
administration. The animal dose was calculated following the
method described by Sengupta et al.43 considering 40 mg as a
human adult dose. The total study duration was 12 h.
At predetermined time intervals of 0.5, 1, 2, 4, 6, 8, and 12 h
after dosing, 0.3−0.4 mL of blood sample was collected into
ethylenediaminetetraacetic acid (EDTA) containing tubes
from each rat through a retro-orbital artery. The rats were
anesthetized every time by intraperitoneal pentobarbital
injection. The samples were immediately centrifuged at 3000
rpm for 10 min. Separated plasma was collected and stored
under −20 °C.
Plasma Extraction and Sample Analysis. Before
extraction, frozen plasma samples were thawed to ambient
temperature. Pioglitazone (10 μL) as an internal standard (IS),
equivalent to 5 μg/mL in plasma, was pipetted to 90 μL of
each plasma sample in a centrifuge tube and vortexed for 1
min. The sample was then extracted with 1.5 mL of ethanol by
vortex mixing for 5 min. The mixture was then centrifuged at
3000 rpm for 10 min to separate the organic layer. This organic
layer was subjected to drying under a gentle stream of nitrogen.
The dried residue was reconstituted with 200 μL of mobile
phase and injected onto the HPLC system after filtering
through a 0.22 μm PTFE syringe filter.
Quantitation of telmisartan was done by the HPLC method.
The method was developed for biological sample analysis with
slight modification in the mobile phase composition and run
time of the analytical HPLC method, as described earlier
(Selection of Optimum Formulation Based on In Vitro
Dissolution Study) in this article. The HPLC parameters of
the employed method were the following: reversed-phase;
elution mode, isocratic; column, ZORBAX Eclipse Plus C18
(250 mm length, 4.6 mm internal diameter, 5 μm pore size);
column temperature, ambient; mobile phase, 50:50 (v/v%)
mixture of acetonitrile and 10 mM phosphate buffer solution
(pH 3.8); flow rate, 1 mL/min; injection volume, 10 μL;
chromatographic run time, 14 min; and detection, UV at 231
nm wavelength. The HPLC method was validated before
analysis with a linear response within a range of 0.07−10 μg/
mL. The accuracy and intraday and interday precision of the
method were established following the standard acceptance
criteria of bioanalytical method validation.44 The developed
linearity plot was used to quantitate telmisartan in the plasma
sample.
Pharmacokinetic Parameters and Relative Bioavail-
ability. Plasma concentrations of telmisartan vs time point
data were analyzed by noncompartmental analysis. The
maximum plasma concentration (Cmax) and time to reach
Cmax (tmax) were derived from the constructed plasma
concentrations vs time plot. The area under curve (AUC0−t)
was calculated for every animal using the trapezoidal rule.
AUC0−∞ were calculated from AUC0−t, last detectable
concentration, and elimination rate constant (kel). kel was
calculated from the slope of the elimination phase. Finally,
relative bioavailability was calculated comparing AUC0−∞ data
of one formulation with another following eq 2.
rel. bio. of formulation 1
AUC of formulation 1






where rel. bio. of formulation 1 is the relative bioavailability of
“formulation 1” with respect to that of “formulation 2.”
All pharmacokinetic data were subjected to ANOVA analysis
(t-test) to evaluate the statistical significance of the difference
between “means” of each group considering a 5% level of
significance (p value < 0.05).
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